TG40 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €1.13
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€337.76K
Enterprise Value€11.66
Total Cash (Recent Filing)€455.00K
Total Debt (Recent Filing)€11.33M
Price to Earnings (P/E)―
Beta-0.91
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,734,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oxurion NV News
TG40 FAQ
What was Oxurion NV’s price range in the past 12 months?
Oxurion NV lowest stock price was €0.01 and its highest was €1.13 in the past 12 months.
What is Oxurion NV’s market cap?
Oxurion NV’s market cap is €337.76K.
When is Oxurion NV’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oxurion NV’s earnings last quarter?
Currently, no data Available
Is Oxurion NV overvalued?
According to Wall Street analysts Oxurion NV’s price is currently Overvalued.
Does Oxurion NV pay dividends?
Oxurion NV does not currently pay dividends.
What is Oxurion NV’s EPS estimate?
Oxurion NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxurion NV have?
Oxurion NV has 140,734,900 shares outstanding.
What happened to Oxurion NV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxurion NV?
Currently, no hedge funds are holding shares in DE:TG40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxurion NV
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.